Opthea (ASX:OPT) completed its drug product process performance qualification campaign for its sozinibercept drug candidate to treat wet age-related macular degeneration, demonstrating its ability to consistently manufacture the candidate at a commercial scale, according to a Wednesday Australian bourse filing.
The campaign consisted of the production of three consecutive commercial-scale drug product batches.
This was required to further validate its manufacturing process in preparation for a potential biologics license application filing, as well as the commercialization of sozinibercept, in the first half of 2026.
The firm's shares fell 5% in early trading on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。